Better Value, Quicker Access
I

n 2017, we continued to bring global payers, industry leaders, clinicians, regulators, patients, HTAs, and other stakeholders together to work towards our overarching goal of bringing high-quality medicines to patients faster:

  • Together with the Boston Consulting Group (BCG) we held two focus groups and one Market Access Roundtable about the sustainability of healthcare funding to develop a common set of standards for future market access competencies.


Why we care: As medicines become increasingly innovative and sophisticated, rising manufacturing costs often render life-saving treatments out of reach for patients. The question of how to expedite patient access to affordable, high-quality healthcare is particularly pressing in an ecosystem where stakeholder goals such as cost containment, profitability, high quality, timely access, and affordability are frequently at odds with each other.


Why we care: As medicines become increasingly innovative and sophisticated, rising manufacturing costs often render life-saving treatments out of reach for patients. The question of how to expedite patient access to affordable, high-quality healthcare is particularly pressing in an ecosystem where stakeholder goals such as cost containment, profitability, high quality, timely access, and affordability are frequently at odds with each other.

In any field, success depends on shared goals that unite the interests and activities of all stakeholders. In the Value and Access space, our role is to foster communication and break down barriers.

Over the past year, DIA roundtables, meetings, and publications have delivered fresh insights and clear perspectives on the most discussed topics, including value frameworks to assess health technologies, drug pricing revisions and reimbursements, the use of real world evidence, access to generics and biosimilars, outcomes-based agreements with drug makers, the “Right to Try,” and early access to innovative drugs.

  • In an article published in Outsourcing Pharma, we reflected on major global trends in drug development that affect patient outcomes as various steps of healthcare product development and delivery are outsourced or shared.
  • We published the outcome of the BCG focus groups and Market Access Roundtable in In Vivo. A second manuscript is currently in process, and a new working group is tasked with establishing a roadmap to a common set of standards for market access.
  • In the Approval and Access: Overcoming the Final Hurdle of Drug Development webinar, European experts debated how life sciences companies, payers, and providers can best respond to the move towards greater collaboration and transparency across countries.
  • Another webinar, Can Europe Bring the Next Generation of Biotech Therapies to Market?, discussed the challenges to Europe’s Advanced Therapy Medicinal Products (ATMP) sector, offering concrete suggestions on how new Advanced Therapies can be brought to patients.
  • Our first Value and Access workshop, Value, Access, and Regulatory Strategy Workshop, engaged regulators and representatives from several HTA bodies to provide scientific advice for tangible solutions addressing the fragmented healthcare industry in Europe.

In 2018, DIA will continue to monitor, share, and respond to the latest developments in the Value and Access landscape as well as convene all stakeholders to address the most pressing issues and re-imagine the future of health economics worldwide. We already started off the New Year with two conferences in Singapore and Morocco that focused on improving access to innovative medicines in Asia’s pandemic disease regions and the Maghreb region, respectively.

Value and Access Workshop, Basel
Back to Report